Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunophage Biotech (Shanghai) Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter indicates a highly focused or early-stage prosecution phase for the company portfolio. Practitioners should note that the entire pending workload is concentrated under 1 distinct examiner and 1 distinct art unit, suggesting a very narrow channel of interaction with the USPTO at this time.
The busiest examiner for this portfolio is ROCHELLE, CIERRA MARIE, who is responsible for 1 pending office action. Because the busiest examiner pending count of 1 matches the total pending office actions of 1, the company faces no examiner-based diversification in its current pipeline. This concentration means that the outcome of the portfolio's active prosecution rests entirely on the interpretations and practices of a single individual within the specified art unit.
Strategic planning for this portfolio requires a deep understanding of the specific examiner's historical tendencies, as there are no other active cases to provide internal benchmarks. The alignment of 1 distinct examiner with 1 distinct art unit simplifies the administrative tracking but increases the impact of any single procedural delay or rejection. Future filings may determine if the company maintains this concentrated approach or expands into additional art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROCHELLE, CIERRA MARIE | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843688 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | ROCHELLE, CIERRA MARIE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843688 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | ROCHELLE, CIERRA MARIE | 1627 | §103§112 | Non-Final OA | — | Pending | Sep 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunophage Biotech (Shanghai) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Cierra Marie Rochelle has the most, with 1 of Immunophage Biotech (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
